Highlights BiomX Inc.

Equities

PHGE

US09090D1037

Market Closed - Nyse Other stock markets 01:40:00 11/05/2024 am IST			5-day change	1st Jan Change
0.3546 ^USD	-1.50%		-7.63%	+26.64%

18/04	Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board	CI
03/04	Transcript : BiomX Inc., Q4 2023 Earnings Call, Apr 03, 2024

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Biomx Inc. Appoints Susan Blum to Its Board of Directors and Member and Chair of the Audit Committee of the Board	18/04	CI
BiomX Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03/04	CI
BiomX Inc. completed the acquisition of Adaptive Phage Therapeutics, Inc.	15/03	CI
BiomX Shares Rally After Merger Deal With Adaptive Phage Therapeutics	06/03	MT
BiomX Inc. agreed to acquire Adaptive Phage Therapeutics, Inc. for $11.5 million.	06/03	CI
Biomx Announces Positive Topline Results from Part 2 of the Phase 1B/2A Trial Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis	29/11	CI
BiomX Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Biomx to Present Data from Ongoing Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis	27/23/27	CI
BiomX Inc. Announces Completion of Patient Dosing in Part 2 of Phase 1b/2a Study Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis	04/23/04	CI
BiomX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	09/23/09	CI
Biomx Inc. to Present Part 1 Data from Phase 1B/2A Study Evaluating Bx004 for the Treatment of Chronic Pseudomonas Aeruginosa Pulmonary Infections in Patients with Cystic Fibrosis During Late-Breaking Science Session At The46th European Cystic Fibrosis Conference	31/23/31	CI
BiomX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/23/16	CI
BiomX Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
BiomX Announces Positive Results from Part 1 of the Phase 1B/2A Study Evaluating Bx004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis	22/23/22	CI
BiomX Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	09/22/09	CI
BiomX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	10/22/10	CI
BiomX Inc. Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease	04/22/04	CI
BiomX to Delist from Tel Aviv Stock Exchange	06/22/06	MT
BiomX to Collaborate With Boehringer Ingelheim to Identify Inflammatory Bowel Disease Biomarkers	28/22/28	MT
BiomX Inc. Announces Dosing of the First Two Patients in Phase 1B/2A Study of Bx004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis	27/22/27	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BiomX Inc.

Equities

PHGE

US09090D1037

Highlights

Filters